Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders

被引：368

作者：

Abe, Ted ^{[1
]}

Zukin, R. Suzanne ^{[2
]}

机构：

[1] Univ Penn, Dept Biol, Philadelphia, PA 19104 USA

[2] Albert Einstein Coll Med, Dominick P Purpura Dept Neurosci, New York, NY 10461 USA

来源：

CURRENT OPINION IN PHARMACOLOGY | 2008年 / 8卷 / 01期

关键词：

D O I：

10.1016/j.coph.2007.12.002

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Epigenetic chromatin remodeling and modifications of DNA represent central mechanisms for regulation of gene expression during brain development and in memory formation. Emerging evidence implicates epigenetic modifications in disorders of synaptic plasticity and cognition. This review focuses on recent findings that HDAC inhibitors can ameliorate deficits in synaptic plasticity, cognition, and stress-related behaviors in a wide range of neurologic and psychiatric disorders including Huntington's disease, Parkinson's disease, anxiety and mood disorders, Rubinstein-Taybi syndrome, and Rett syndrome. These agents may prove useful in the clinic for the treatment of the cognitive impairments that are central elements of many neurodevelopmental, neurological, and psychiatric disorders.

引用

页码：57 / 64

页数：8

共 56 条

[1] Chromatin acetylation, memory, and LTP are impaired in CBP+/- mice:: A model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration [J].